Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Bromazepam→

Bromazepam Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1812-30-2
Molecular formula
C14H10BrN3O
Molecular weight
316.15 g/mol
Drug class
Benzodiazepine anxiolyticGABAA-receptor positive allosteric modulator
Mechanism of action
Binds to the benzodiazepine site on GABAA receptors and enhances the inhibitory effect of GABA, increasing chloride-channel opening frequency and reducing neuronal excitability.
Indications / reported uses
  • Short-term symptomatic treatment of severe anxiety in adults when symptoms are disabling or cause significant distress, in countries where bromazepam is authorised; prolonged use is discouraged because of tolerance and dependence risks

Sources: NLM MeSH — Bromazepam · PubMed — Bromazepam pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Bromazepam Environmental Risk Assessment (ERA) (the Bromazepam ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.